Table 5 Adjusted MD (%95CI) and adjusted SMD (%95CI) for biomarkers of fatty liver
Intervention (N = 69) | Control (N = 50) | ||||
|---|---|---|---|---|---|
Mean (SD) | MD (95%CI) | SMD (%95CI) | |||
ALT* | Baseline | 71.33 (49.35) | 47.52 (7.46) | - | - |
Month 3 | 41.48 (2.12) | 43.46 (1.08) | -6.58 (-11.35, -1.82) | -0.47 (-0.84, -0.1) | |
Month 6 | 30.16 (1.33) | 42.9 (1.12) | -15.33 (-18.8, -11.88) | -1.73 (-2.16, -1.31) | |
AST* | Baseline | 46.74 (14.14) | 42.54 (11.61) | - | - |
Month 3 | 35.65 (1.24) | 39.42 (1.46) | -5.97 (-8.83, -3.1) | -0.6 (-0.96, -0.22) | |
Month 6 | 28.34 (0.99) | 39.2 (1.54) | -12.82 (-15.5, -10.13) | -1.46 (-1.86, -1.05) | |
ALKp* | Baseline | 186.91 (66.43) | 197.98 (40.30) | - | - |
Month 3 | 176.52 (7.32) | 195.34 (5.53) | -10.28 (-2.2, 0.63) | -0.19 (-0.55, 0.17) | |
Month 6 | 183.12 (7.67) | 196.8 (5.57) | -4.1 (-13.08, 4.88) | -0.07 (-0.44, 0.29) | |
GGT* | Baseline | 59.s55 (26.09) | 42.07 (9.52) | - | - |
Month 3 | 41.91 (19.90) | 42.68 (11.70) | -9.36 (-14.34, -4.38) | -0.74 (-1.11, -0.36) | |
Month 6 | 34.01 (14.80) | 41.48 (10.82) | -15.58 (-18.68, -12.47) | -1.97 (-2.41, -1.52) | |
SBP** | Baseline | 118.19 (11.42) | 120.86 (9.10) | - | - |
Month 3 | 115.62 (11.34) | 120.60 (8.61) | -2.84 (-5.26, -0.42) | -0.43 (-0.80, -0.7) | |
Month 6 | 112.32 (10.73) | 120.70 (8.81) | -6.31 (-8.65, -3.97) | -0.87 (-1.25, -0.5) | |